AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00571636 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Description: The experimental drug will be diluted according to each NICU scheme and administered as an attach dose of 1 mcg/kg in 30' followed by continuous i.v. infusion of 1 mcg/kg/h. Infusion of the experimental drug has to begin within 24 hrs from the beginning of MV and has to be continued until the end of MV and not after 7 days of life. If the newborn is still on MV after the 7th day of life he/she will be treated for pain according to local protocols.~Open label boluses of Fentanyl during the study phase will be administered, in both groups when the EDIN pain score is > 6 and before performing the following invasive procedures:Peripherally inserted central venous catheter positioning;Re-intubation;Lumbar puncture;Pneumothorax or hydrothorax drainage.
Study NCT00571636 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 5% glucose solution
Description: ev continuous infusion
Study NCT04589351 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ezetimibe 10mg
Description: Ezetimibe is a cholesterol absorption inhibitor with marketing approval. The recommended dose as per label is 10mg once a day.
Study NCT04589351 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo
Study NCT03795207 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: SBRT + Durvalumab
Description: Durvalumab, MEDI4736, is a immunotherapy,~SBRT (stereotactic body radiotherapy) is a procedure that uses high doses of radiation delivered to a precise target. By using special positioning and implanted markers in the body, radiologists are able to deliver a much higher dose of radiation to a cancer than traditional radiation therapy
Study NCT03795207 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: SBRT
Description: SBRT (stereotactic body radiotherapy) is a procedure that uses high doses of radiation delivered to a precise target. By using special positioning and implanted markers in the body, radiologists are able to deliver a much higher dose of radiation to a cancer than traditional radiation therapy
Study NCT05366491 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Il-38 serum level
Description: measurement of serum levels of IL-38
Study NCT03310008 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NKR-2 cells
Description: The intervention will consist of an infusion of NKR-2 cells administered concurrently to a standard chemotherapy every 2 weeks (14 days) for a total of 3 infusions within 4 weeks (28 days).
Study NCT04179565 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Healthy Children Healthy Families
Description: The Healthy Children, Healthy Families: Parents Making a Difference! intervention was developed by the investigators for low-income parents and caregivers focusing on the behaviors most likely to help children avoid unhealthy weight gain.
Study NCT03493009 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pure-Vu System
Description: The Pure-Vu System is Food and Drug Administration (FDA) approved device since September 22, 2016, intended to connect to standard colonoscopes to help facilitate intra-procedural cleaning of a poorly prepared colon by irrigating or cleaning the colon and evacuating the irrigation fluid (water), feces and other bodily fluids and matter, e.g. blood.
Study NCT03194256 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Spectrum Research Cigarettes
Description: Participants will be assigned to either normal nicotine content cigarettes or very low nicotine content cigarettes.
Study NCT03866343 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Diet low or high in advanced glycation endproducts
Description: All subjects will undergo an intervention consisting of a prescribed diet containing either a low or high quantity of AGEs during 4 continuous weeks.
Study NCT03866343 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Diet low or high in advanced glycation endproducts
Description: All subjects will undergo an intervention consisting of a prescribed diet containing either a low or high quantity of AGEs during 4 continuous weeks.
Study NCT03420469 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupropion
Description: Phase 1: Baseline CYP2D6 activity, using dextromethorphan (30 mg single dose PO) as a probe drug Phase 2: Single dose bupropion pharmacokinetics and its effect on CYP2D6 activity (determined by dextromethorphan 30 mg single dose PO) Phase 3: Steady state disposition of bupropion and its interaction with CYP2D6 activity (30 mg single dose PO)
Study NCT02626520 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine and nanoparticle albumin bound paclitaxel
Description: Gemcitabine and nab-paclitaxel given every 14 days x 4 cycles
Study NCT02626520 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-fluorouracil and irinotecan
Description: FOLFIRI.3 given every 14 days x 4 cycles
Study NCT02626520 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Preoperative chemoradiation
Description: Pre-operative chemoradiation to 40 Gy in 20 fractions
Study NCT02626520 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Definitive resection
Description: Definitive surgical resection of primary tumor
Study NCT02014844 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 250 mg/m2 aldoxorubicin
Study NCT02014844 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 350 mg/m2 aldoxorubicin
Study NCT00407888 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin hydrochloride
Description: Given IV
Study NCT00407888 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Given orally
Study NCT00407888 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim
Description: Given SC
Study NCT00407888 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel albumin-stabilized nanoparticle formulation
Description: Given IV
Study NCT00407888 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: trastuzumab
Description: Given IV
Study NCT00407888 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT00407888 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: quality-of-life assessment
Description: Ancillary studies
Study NCT03281928 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Sodium and Potassium Citrate
Description: Sodium and potassium citrate levels will be altered in diet and renal mineral handling will be measured as compared to placebo.
Study NCT03281928 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sodium without Potassium Citrate
Study NCT04364230 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 6MHP
Description: 6 melanoma helper vaccine comprised of 6 class II MHC-restricted helper peptides
Study NCT04364230 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NeoAg-mBRAF
Description: BRAF 586-614 (V600E) peptide to which a histidine has been added to the N-terminus, resulting in BRAF 585-614 (V600E).
Study NCT04364230 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PolyICLC
Description: polyICLC, local adjuvant
Study NCT04364230 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CDX-1140
Description: CDX-1140, local adjuvant
Study NCT01934452 — intervention group
Intervention type: DRUG
Intervention: sunitinib
Description: 50 mg 4/2 ,oral, once a day 4 weeks on and 2 weeks off for 6 months
Study NCT03208465 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin
Description: In empagliflozin group, patients will be prescribed empagliflozin 10mg/day.
Study NCT03194256 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Spectrum Research Cigarettes
Description: Participants will be assigned to either normal nicotine content cigarettes or very low nicotine content cigarettes.
Study NCT01521637 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Neuromuscular Electrical Stimulation of m. quadriceps femoris
Description: Neuromuscular Electrical Stimulation of m. quadriceps femoris by using a commercially available muscle stimulator
Study NCT01521637 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham-treatment: no NMES
Description: Sham comparator
Study NCT03208465 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sitagliptin
Description: In sitagliptin group, patients will be prescribed sitagliptin 100mg/day.
Study NCT03001635 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin
Description: 26 patients will receive Oxytocin infusion for 6h while 26 will receive placebo. all other treatments will be the same and up to date with the current guidelines.
Study NCT03001635 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: 26 patients will receive 0.9% normal saline infusion for 6h as placebo
Study NCT03541525 — intervention group
Intervention type: OTHER
Intervention: Biological sampling
Description: Biological samples including blood, surgical remainder, urine,...
Study NCT02276599 — intervention group
Intervention type: PROCEDURE
Intervention: Volume expansion
Description: Fluid bolus of 0.9% normal saline 10 mL/kg over 10 minutes
Study NCT01218009 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Spiromax
Description: Placebo as a dry-powder inhaled orally using the Spiromax inhaler. During the 12-week double-blind period, participants take two (2) inhalations four times a day (QID) at approximately 7:00 AM, 12:00 PM, 5:00 PM, and bedtime.
Study NCT01218009 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albuterol Spiromax
Description: Albuterol as a dry-powder inhaled orally using the Spiromax inhaler. Each inhalation delivers 90 micrograms (mcg). During the 12-week double-blind period, participants take two (2) inhalations four times a day (QID) at approximately 7:00 AM, 12:00 PM, 5:00 PM, and bedtime for a total dose of 720 micrograms per day for those paricipants randomized to the Albuterol treatment arm.~The double-blind period is followed by a 40-week open-label period in which all study participants will take Albuterol Spiromax 90 micrograms (mcg)/inhalation as needed (PRN).
Study NCT01218009 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Albuterol Spiromax
Description: Albuterol as a dry-powder inhaled orally using the Spiromax inhaler. Each inhalation delivers 90 micrograms (mcg). During the 12-week double-blind period, participants take two (2) inhalations four times a day (QID) at approximately 7:00 AM, 12:00 PM, 5:00 PM, and bedtime for a total dose of 720 micrograms per day for those paricipants randomized to the Albuterol treatment arm.~The double-blind period is followed by a 40-week open-label period in which all study participants will take Albuterol Spiromax 90 micrograms (mcg)/inhalation as needed (PRN).
Study NCT03491540 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sennosides colonic preparation
Description: Mechanical bowel preparation :~Sennosides colonic preparation (X-PREP)~1 per day, on day -2 and day -1
Study NCT03491540 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sennosides colonic preparation
Description: Mechanical bowel preparation :~Sennosides colonic preparation (X-PREP)~1 per day, on day -2 and day -1
Study NCT03491540 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Gentamycin
Description: Oral gentamycin:~Gentamycin 80 mg, 4 per day, on day -2 and day -1; Liquid forms in individual vials
Study NCT03491540 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Ornidazole
Description: Oral ornidazole :~Ornidazole~1 g per day (2 tablet per day), on day -2 and day -1; In tablets
Study NCT03378284 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tegoprazan
Description: Tegoprazan QD for 7 days
Study NCT03378284 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Revaprazan
Description: Revaprazan QD for 7 days
Study NCT01035216 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GNKG168
Description: GNKG168 will be administered as a 60 minute IV infusion once daily for 5 days followed by a 9 day rest period.
Study NCT03698370 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gallium Ga 68 DOTA-NeoBOMB1
Description: Administered intravenously (IV)
Study NCT03491540 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Oral Placebo Gentamycin
Description: Placebo for oral gentamycin :~Same presentation as oral gentamycin x4 per day on day -2 and day -1
Study NCT03491540 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Oral Placebo Ornidazole
Description: Placebo for oral ornidazole :~Same presentation as oral ornidazole~1g per day (2 tablets per day) on day -2 and day -1
Study NCT03451695 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Morphine
Description: Morphine group will receive intrathecal 11 mg of hyperbaric bupivacaine (2.2 mL 0.5%), 10 μg of fentanyl (0.2 ml) and 100 μg of preservative free morphine (0.1 ml).
Study NCT03451695 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo group will receive 11 mg of hyperbaric bupivacaine (2.2 mL 0.5%), 10 μg of fentanyl (0.2 ml) and normal saline (0.1ml)
Study NCT03700554 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pleuralvent™
Description: Pneumothorax treatment with Pleuralvent™ device (Heimlich valve device)
Study NCT03700554 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Chest tube
Description: Chest tube insertion
Study NCT01253213 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BR55
Description: One to two bolus (2nd bolus optional) of BR55 per patient
Study NCT03154775 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: C-CAR011
Description: Autologous 2nd generation CD19-directed CAR-T cells, single infusion intravenously at a target dose of 0.5-5.0 x 10\^6 anti-CD19 CAR+ T cells/kg
Study NCT00109031 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: palifermin
Description: Administered as one daily intravenous bolus.
Study NCT00109031 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: palifermin
Description: Administered as one daily intravenous bolus.
Study NCT00109031 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total Body Irradiation
Description: To be delivered before the administration of chemotherapy in 6, 8, or 10 fractions over 3 or 4 days.
Study NCT03698370 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Gallium Ga 68 PSMA-R2
Description: Administered intravenously (IV)
Study NCT02005718 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cholecalciferol
Study NCT00933387 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab,Paclitaxel,Cisplatin
Description: Cetuximab 500 mg/m2 iv infusion (120 min for the 1st infusion, 90 min for the 2nd , and 60 min for the subsequent) Paclitaxel 120 mg/m2 3-hour iv infusion Cisplatin 50 mg/m2 2-hour iv infusion
Study NCT00109031 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Total Body Irradiation
Description: To be delivered before the administration of chemotherapy in 6, 8, or 10 fractions over 3 or 4 days.
Study NCT00109031 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide is administered at a total dose of 100 mg/kg given in 1 dose on Day -2
Study NCT00109031 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: Cyclophosphamide is administered at a total dose of 100 mg/kg given in 1 dose on Day -2
Study NCT00109031 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Etoposide may be administered (optional) as a single intravenous infusion over 4 hours on the day after the last fTBI fraction.
Study NCT00109031 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etoposide
Description: Etoposide may be administered (optional) as a single intravenous infusion over 4 hours on the day after the last fTBI fraction.
Study NCT00109031 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered as one daily intravenous bolus.
Study NCT00109031 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Administered as one daily intravenous bolus.
Study NCT02359916 — intervention group
Intervention type: OTHER
Intervention: Time delays on delivery of less healthy snacks
Study NCT02359916 — intervention group
Intervention type: OTHER
Intervention: 25%/$0.25 discount on healthy snacks
Study NCT02359916 — intervention group
Intervention type: OTHER
Intervention: 25%/$0.25 tax on less healthy snacks
Study NCT01360918 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Epicardial pulmonary vein isolation
Description: After the CABG procedure, a bilateral epicardial pulmonary vein isolation is performed under general anaesthesia and double-lumen endotracheal ventilation.
Study NCT01360918 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Management of atrial fibrillation according to current guidelines using rate control pharmacological therapy.
Study NCT01328496 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Preparative Regimen
Description: Fludarabine (75 mg/m2), fractionated total body irradiation (TBI) (12.0 Gy), and cyclophosphamide (120mg/kg) with mesna. Fludarabine will be given once a day at 25 mg/m2 for three days on day -10 to day -8, TBI will be given twice a day at 150 cGy for four days on day -7 to day -4, and cyclophosphamide will be given once a day for at 60mg/kg for two days on day -3 and day -2.~Post-transplantation immunosuppression with cyclosporine and MMF will begin on day -3. Cord Blood infusion will occur on day 0 and G-CSF will start on day +1.
Study NCT01744340 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Head and neck
Description: Eribulin mesylate is administered by IV infusion over 2-5 minutes on day 1 and 8 of a 21 day cycle 1.4mg/m2 and Cetuximab 400 mg/m2 cycle 1 week 1, then 250 mg/m2/weekly thereafter~Dose Level 1: 0.7 mg/m2 IV infusion days 1 and 8 of 21 day cycle Dose Level 2: 1.0 mg/m2 IV infusion days 1 and 8 of 21 day cycle Dose Level 3: 1.4 mg/m2 IV infusion days 1 and 8 of 21 day cycle
Study NCT00188305 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: General health counselling and risk information
Description: General health counselling and risk information
Study NCT00188305 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: General health counselling and risk information
Description: General health counselling and risk information
Study NCT00188305 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: General health counselling and risk information
Description: General health counselling and risk information
Study NCT00705159 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: loteprednol etabonate and tobramycin
Description: Topical ocular administration of loteprednol etabonate and tobramycin 4 times per day (QID) for 14 days.
Study NCT00705159 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: loteprednol etabonate
Description: Topical ocular administration of Lotemax (loteprednol etabonate) QID for 14 days.
Study NCT00705159 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tobramycin
Description: Topical ocular administration of Tobramycin QID for 14 days.
Study NCT00705159 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle of Zylet
Description: Topical ocular administration of the vehicle of Zylet QID for 14 days.
Study NCT04864782 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QL1604
Description: Intravenous Infusion
Study NCT04864782 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel injection
Description: Intravenous Infusion
Study NCT04864782 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin/Carboplatin
Description: Intravenous Infusion
Study NCT03488550 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ANX007
Description: Single ascending dose
Study NCT01918176 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib alone
Description: Single dose of 125mg Palbociclib capsule will be administered to subjects orally and then PK samples will be collected at 1, 2, 4, 6, 8, 12, 24, 48, 72, 96 and 120 hours.
Study NCT01918176 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib + Rabeprazole
Description: Two Rabeprazole 20mg tablets will be given to subjects orally once daily for 7 days. Then on the same day at least 4 hours after the last dose of Rabeprazole, single dose of 125mg Palbociclib capsule will be given to subjects orally then followed by PK samplings at 1, 2, 4, 6, 8, 12, 24, 48, 72, 96 and 120 hours.
Study NCT03710252 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paritaprevir/ritonavir/ombitasvir + dasabuvir +/- ribavirin
Description: OMB/PTV/r + DSV +/- RBV
Study NCT03636854 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Concentric exercises
Description: Resistance concentric straight leg raise and knee extension will be done.
Study NCT03636854 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Eccentric exercises
Description: Resistance eccentric straight leg raise and knee extension will be done.